Ocular Therapeutix's Stock Gets A Shock As Another PhIII Misses Target
Ocular Therapeutix Inc.'s stock plummeted 42% on June 6 after a second Phase III study of its allergic conjunctivitis therapy, Dextenza (sustained-release dexamethasone), failed to reach its single primary endpoint – another big hit for the drug following a Phase III failure in ocular inflammation in 2015.
You may also be interested in...
The long-acting eye insert Dextenza has been accepted for review by the US FDA, a piece of good news for Ocular Therapeutix that had previously received a complete response letter on manufacturing issues and a mixed bag of late-stage clinical trial results.
Regeneron is partnering with the troubled ophthalmology-focused biotech to develop a sustained-release formulation of Eylea that could enable a less-frequent dosing regimen.
The latest drug development news and highlights from our FDA Performance Tracker.